Better Health for All

Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for conditions such as multiple sclerosis, idiopathic pulmonary fibrosis, depression, and chronic pain.

While the company's mission is to address unmet medical needs, its products are still in clinical development. One drug candidate, PIPE-307, failed to meet its primary and secondary efficacy endpoints in a Phase 2 trial for relapsing/remitting multiple sclerosis, although it demonstrated acceptable safety and tolerability. Other candidates are in earlier phases, with results for a Phase 2 trial in major depressive disorder expected by mid-2026. The company has raised $194 million in private funding and is seeking an IPO to advance drug development, but no specific percentage of R&D or capital allocation for health improvement is provided. Clinical trials are described as randomized, double-blind, placebo-controlled, and multi-center, with an intent to publish full results, but there is no specific evidence of ethical frameworks or inclusion practices that would map to a numerical tier.

Fair Trade & Ethical Sourcing

No specific, concrete, or quantitative data regarding Contineum Therapeutics, Inc.'s fair trade and ethical sourcing practices, supplier audits, child/forced labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, high-risk material spend, or supplier diversity spend was found in the provided articles.

The company's Code of Conduct outlines general ethical principles and expectations for fair dealing but does not provide measurable outcomes or specific metrics relevant to the KPIs.

Kind to Animals

Contineum Therapeutics conducts preclinical studies using animal models, including rodents and minipigs for toxicology and proof-of-concept, and mice for drug testing.

The company also performs chronic toxicity studies for its drug candidates. While in vitro studies using human cells are mentioned, the majority of safety and efficacy testing appears to rely on animal models. No specific animal testing policy is disclosed, nor are there transparent reduction targets for animal testing volume. The number of animals used annually is not provided, but multiple animal studies are mentioned. The company's R&D expenses were $38.422 million for the year ended December 31, 2024, but there is no evidence of any portion of this budget being allocated to animal-free technologies. There is no evidence of participation in multi-stakeholder initiatives to develop industry-wide animal-free testing and sourcing standards, nor any cruelty-free certifications for its products.

No War, No Weapons

No relevant data was found in the provided articles to assess Contineum Therapeutics, Inc. against the 'No War, No Weapons' ethical value. The articles consisted of a website's terms of use

, a general ESG data listing without specific metrics , and an inaccessible SEC filing , none of which contained information pertinent to the defined KPIs.

Planet-Friendly Business

The provided article from Biospace.com is a news aggregator for Contineum Therapeutics (CTNM.US) and does not contain any quantitative data relevant to the company's environmental, social, and governance (ESG) performance or planet-friendly business practices.

Therefore, no metrics from the requested list can be extracted or scored.

Zero Waste & Sustainable Products

No specific, concrete data points for Contineum Therapeutics, Inc. (CTNM.US) were found across any of the provided articles for the 'Zero Waste & Sustainable Products' KPIs.

The articles either explicitly stated a lack of data for CTNM.US or discussed general industry trends without attributing specific actions or metrics to the company. While mentions the company's use of hazardous materials in laboratory operations and associated environmental regulations, it does not provide any quantitative or qualitative information on the company's hazardous waste management practices, minimization efforts, or compliance record, thus preventing a score for this KPI.